WHO ICTRP trial
Exploratory study for the usefulness of early introduction of anifrolumab in the…
JPRN-jRCTs031230358 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCTs031230358 |
|---|---|
| Public title | Exploratory study for the usefulness of early introduction of anifrolumab in the first remission induction therapy for systemic lupus erythematosus |
| Scientific title | Exploratory study for the usefulness of early introduction of anifrolumab in the first remission induction therapy for systemic lupus erythematosus |
| Primary sponsor | Tsuboi Hiroto |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Conditions | systemic lupus erythematosus |
| Interventions | Anifrolumab is started within 2 weeks after PSL initiation, and thereafter anifrolumab 300 mg is administered intravenously over 30 minutes every 4 weeks according to the anifrolumab package insert. The treatment period of anifrolumab… |
| Registration date | Sep 22, 2023 |
| Target size | 10 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: